SCHEMBL2930813

SCHEMBL2930813

Cc1cc(C(=O)Cl)c(C)n1C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 4/20 0.44
CTDSP1 Q9GZU7 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
ALDH1A1 P00352 6/20 0.42
MAPT P10636 5/20 0.42
RAB9A P51151 4/20 0.42
LMNA P02545 2/20 0.42
KMT2A Q03164 2/20 0.41
KDM4E B2RXH2 2/20 0.40
PKM P14618 2/20 0.40
MAPK1 P28482 2/20 0.40
NPC1 O15118 3/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
GAA P10253 1/20 0.39
RECQL P46063 1/20 0.39
MEN1 O00255 1/20 0.38
NOTUM Q6P988 1/20 0.38
NPSR1 Q6W5P4 2/20 0.38
USP2 O75604 1/20 0.38
TP53 P04637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10371971 0.80 MAPT (0.42) L3MBTL1CTDSP1TDP1ALDH1A1MAPT
SCHEMBL1041466 0.80 NOTUM (0.53) ALDH1A1KMT2AMEN1NOTUM
SCHEMBL13740220 0.78 ALDH1A1 (0.55) L3MBTL1CTDSP1TDP1ALDH1A1MAPT
SCHEMBL13687490 0.75 L3MBTL1 (0.39) L3MBTL1CTDSP1TDP1ALDH1A1MAPT
SCHEMBL6971384 0.75 KDM4E (0.48) L3MBTL1CTDSP1TDP1ALDH1A1MAPT
SCHEMBL6971381 0.74 L3MBTL1 (0.48) L3MBTL1CTDSP1TDP1ALDH1A1MAPT
SCHEMBL14226107 0.71 MAPT (0.36) L3MBTL1CTDSP1TDP1ALDH1A1MAPT
SCHEMBL13753346 0.71 BRD4 (0.42) L3MBTL1CTDSP1TDP1ALDH1A1MAPT
SCHEMBL9957119 0.71 NOTUM (0.72) L3MBTL1ALDH1A1MAPTRAB9ALMNA
SCHEMBL17815671 0.71 GAA (0.54) L3MBTL1ALDH1A1RAB9AKMT2AMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2655323-B1 INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES LEO LABORATORIES LTD (IE) 2017-12-20 EP disclosed
US-20170217910-A1 INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES LEO LABORATORIES LIMITED (IE) 2017-08-03 US disclosed
US-9708286-B2 Ingenol-3-acylates III and ingenol-3-carbamates LEO LABORATORIES LIMITED (IE) 2017-07-18 US disclosed
US-20150291551-A1 INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES LEO LABORATORIES LIMITED (IE) 2015-10-15 US disclosed
US-9102687-B2 Ingenol-3-acylates III and ingenol-3-carbamates LEO LABORATORIES LIMITED (IE) 2015-08-11 US disclosed
US-20140303150-A1 INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES LEO LABORATORIES LIMITED (IE) 2014-10-09 US disclosed
EP-2655323-A1 INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES LEO LABORATORIES LIMITED (IE) 2013-10-30 EP disclosed
WO-2012083953-A1 INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES LEO PHARMA A/S (DK) 2012-06-28 WO disclosed
EP-1682549-B1 IMIDAZO[1,2-A]PYRIDINE ANXIOLYTICS SEPRACOR INC (US) 2010-09-22 EP disclosed
US-7723324-B2 Imidazo[1,2-A]pyridine anxiolytics SEPRACOR, INC. (US) 2010-05-25 US disclosed
US-7566725-B2 Imidazo[1,2-A] pyridine anxiolytics SEPRACOR INC. (US) 2009-07-28 US disclosed
US-20080096867-A1 Imidazo[1,2-A] Pyridine Anxiolytics SEPRACOR INC. (US) 2008-04-24 US disclosed
US-20070043074-A1 IMIDAZO[1,2-A] PYRIDINE ANXIOLYTICS SEPRACOR INC. (US) 2007-02-22 US disclosed
US-7148353-B2 Imidazo[1,2-a] pyridine anxiolytics SEPRACOR INC. (US) 2006-12-12 US disclosed
EP-1682549-A2 IMIDAZO[1,2-A]PYRIDINE ANXIOLYTICS Sepracor Inc. (US) 2006-07-26 EP disclosed
US-20050171144-A1 Imidazo[1,2-a] pyridine anxiolytics SEPRACOR INC. (US) 2005-08-04 US disclosed
WO-2005044818-A2 IMIDAZO[1,2-A]PYRIDINE ANXIOLYTICS SEPRACOR, INC. (US) 2005-05-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043074-A1 IMIDAZO[1,2-A] PYRIDINE ANXIOLYTICS CNR1, CNR2, GABRA5 L3MBTL1 4232/4885CTDSP1 4258/4885TDP1 2444/4885
US-20050171144-A1 Imidazo[1,2-a] pyridine anxiolytics CNR1, CNR2, GABRA5 L3MBTL1 4232/4885CTDSP1 4258/4885TDP1 2444/4885
US-20170217910-A1 INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES RXRB, RXRA, RXRG L3MBTL1 3703/4885CTDSP1 3781/4885TDP1 4714/4885
US-20150291551-A1 INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES RXRB, RXRA, RXRG L3MBTL1 3703/4885CTDSP1 3781/4885TDP1 4714/4885
US-20140303150-A1 INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES RXRB, RXRA, RXRG L3MBTL1 3703/4885CTDSP1 3781/4885TDP1 4714/4885
US-20080096867-A1 Imidazo[1,2-A] Pyridine Anxiolytics MTNR1B, ADORA2B, ADRA2B L3MBTL1 2443/4885CTDSP1 4596/4885TDP1 3534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.